Literature DB >> 32969114

In Reply.

Caterina Vivaldi1,2, Lorenzo Fornaro2, Clara Ugolini3, Enrico Vasile2.   

Abstract

Mesh:

Year:  2020        PMID: 32969114      PMCID: PMC7648355          DOI: 10.1002/onco.13538

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


× No keyword cloud information.
  5 in total

Review 1.  Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis.

Authors:  Anne M Horgan; Eitan Amir; Thomas Walter; Jennifer J Knox
Journal:  J Clin Oncol       Date:  2012-04-23       Impact factor: 44.544

2.  Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer.

Authors:  T Ebata; S Hirano; M Konishi; K Uesaka; Y Tsuchiya; M Ohtsuka; Y Kaneoka; M Yamamoto; Y Ambo; Y Shimizu; F Ozawa; A Fukutomi; M Ando; Y Nimura; M Nagino
Journal:  Br J Surg       Date:  2018-02       Impact factor: 6.939

3.  Regarding "HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer".

Authors:  Alessandro Rizzo; Angela Dalia Ricci; Giovanni Brandi
Journal:  Oncologist       Date:  2020-08-13

4.  Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study.

Authors:  John N Primrose; Richard P Fox; Daniel H Palmer; Hassan Z Malik; Raj Prasad; Darius Mirza; Alan Anthony; Pippa Corrie; Stephen Falk; Meg Finch-Jones; Harpreet Wasan; Paul Ross; Lucy Wall; Jonathan Wadsley; Jeff T R Evans; Deborah Stocken; Raaj Praseedom; Yuk Ting Ma; Brian Davidson; John P Neoptolemos; Tim Iveson; James Raftery; Shihua Zhu; David Cunningham; O James Garden; Clive Stubbs; Juan W Valle; John Bridgewater
Journal:  Lancet Oncol       Date:  2019-03-25       Impact factor: 41.316

5.  HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.

Authors:  Caterina Vivaldi; Lorenzo Fornaro; Clara Ugolini; Cristina Niccoli; Gianna Musettini; Irene Pecora; Andrea Cacciato Insilla; Francesca Salani; Giulia Pasquini; Silvia Catanese; Monica Lencioni; Gianluca Masi; Daniela Campani; Gabriella Fontantini; Alfredo Falcone; Enrico Vasile
Journal:  Oncologist       Date:  2020-05-11       Impact factor: 5.837

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.